What tesamorelin is

• What tesamorelin is and why the trans-3-hexenoyl cap makes GHRH(1-44) last longer
• How amplifying pulsatile GH raises IGF-1 and preferentially reduces visceral fat
• How to read the Falutz phase 3 lipodystrophy trials and the NAFLD evidence tier by tier
• How the approved product is dosed and monitored, and its real safety signals
• Where tesamorelin sits among sermorelin, CJC-1295, ipamorelin, MK-677, and recombinant GH
• Its regulatory status: FDA-approved for HIV lipodystrophy only, off-label elsewhere, prohibited in sport

1. 01 What tesamorelin is The only FDA-approved GHRH analog, and what it is actually for free
2. 02 GHRH(1-44) biology and the receptor The full-length hormone, the class B receptor, and one GH pulse paid
3. 03 Stabilization: the hexenoyl cap and DPP-4 resistance One chemical change that turns minutes into a usable daily drug paid
4. 04 Preserved pulsatility and the IGF-1 axis A longer pulse that still returns to baseline, and where the fat goes paid
5. 05 HIV-associated lipodystrophy The one condition tesamorelin was built for, and why paid
6. 06 The Falutz phase 3 trials The pivotal evidence: what the phase 3 program actually showed paid
7. 07 Liver fat: the NAFLD evidence The promising second act: reducing liver fat, still off-label paid
8. 08 Dosing, monitoring, and safety How the approved product is dosed and watched, and what can go wrong paid
9. 09 The GH-axis landscape Tesamorelin among the secretagogues, analogs, and recombinant GH paid
10. 10 Regulatory status and access Approved, narrow, prohibited in sport, and increasingly compounded paid
11. 11 Final exam and certification Pass the final exam to earn your specialist certificate. exam

Before any detail, hold the whole idea in one sentence. Tesamorelin does not pour growth hormone into the body. It gives the pituitary the same signal the hypothalamus uses, the gland releases a pulse of its own GH, and that raises IGF-1, which drives fat breakdown.

Because the pituitary and its feedback loops stay in charge, the response is self-limiting. Working with the axis rather than overriding it is the thread that runs through the whole course.

Tesamorelin, developed as TH9507, answered a specific problem: native GHRH and sermorelin are cleared too fast for practical daily therapy. A stabilizing cap gave GHRH(1-44) a longer action, and the phase 3 program earned it FDA approval in 2010.

The framing that matters is scope. Tesamorelin is approved for one narrow indication, not for general body recomposition, and it remains the only FDA-approved GHRH analog marketed in the US.

The most common misconception is that tesamorelin is a weight-loss drug. It is not. It preferentially reduces visceral fat around the organs while largely sparing the fat under the skin, so total body weight changes little.

This distinction is clinically the point. In HIV lipodystrophy, peripheral fat is often already lost, so a drug that targets the visceral depot and spares the rest is precisely what the population needs.

Tesamorelin invites hype, so set the ceiling before the science. Unlike most peptides in this space, its approved use rests on phase 3 trials, but that strength does not transfer to the off-label promises made around it.

Keeping these tiers apart is the discipline of the course. The lipodystrophy data are genuinely strong, the liver-fat data are promising, and the sweeping non-HIV promises rest on extrapolation. Confusing one tier for another is how honest education slides into marketing.

A few claims you will meet online, held against the tiers above. Most are not simply false. They are real but narrow findings that get rounded up into transformations as they travel from journals to sales pages.

The skill this course builds is reading each claim against its tier. When a source states an exact off-label benefit with confidence, that confidence itself is usually the red flag.